NF-KB p50 DEFICIENT IMMATURE MYELOID CELLS AND THEIR USE IN TREATMENT OF CANCER
AssigneeThe Johns Hopkins University
InventorAlan D. Friedman
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for making autologous bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit (p50). The progenitor cells are expanded, exposed to a myeloid cytokine, and provided intravenously to treat various malignancies. The infused cells have the potential to generate mature granulocytes, monocytes, macrophages, and dendritic cells that are activated due to the absence of p50. Methods for the genetically manipulation of a subject's hematopoietic progenitors during the expansion phase to reduce or eliminate p50 expression are also contemplated, and these progenitor cells may be combined with other therapeutic agents to maximize efficacy.
Claims23
A synthetic hematopoietic progenitor cell or population of cells, wherein expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) p50 protein subunit in said cell or population of cells is reduced when compared to wild-type cells.
A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a synthetic hematopoietic progenitor cell or population of cells, wherein expression of NF-κB p50 protein subunit in said cell or population of cells is reduced when compared to wild-type cells;
- and wherein said disease is a cancer, non-cancerous aberrant cellular proliferation, or an infectious disease.
Dependencies are inferred from the claim text.